Neurology · Sleep DisordersTrial Updateclinicalmid-term

Daridorexant Trial Targets Insomnia and Alcohol Use Disorder

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/17/2026, 12:31:12 AM

Assessment confidence: 63% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing clinical trial of daridorexant could redefine treatment approaches for patients with both insomnia and alcohol use disorder, creating a potential dual-action therapy. Success in this trial may shift market dynamics and influence competitive positioning among existing therapies for these conditions. Regulatory context from FDA (Drug Trials Snapshots: YARTEMLEA) supports the near-term read. Assessment grounded in 20 ranked evidence items (8 high-relevance).

Strategic Assessment

This trial could inform strategic decisions regarding the development of combination therapies and market positioning for sleep medications. The strongest clinical anchor is Daridorexant for People With Insomnia and Alcohol Use Disorder Study (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Sleep Disorders, 3 regulatory and 3 competitive items passed relevance filtering for alcohol use disorder market.

Competitive Pressure

The most relevant competitive pressure comes from Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders (Lilly) — sponsor/company relevance (lilly). Secondary pressure from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study. If successful, daridorexant could position itself as a dual-action treatment in a niche market, potentially impacting competitors focused on either insomnia or alcohol use disorder separately.

Regulatory Outlook

Regulatory risk is concentrated around Drug Trials Snapshots: YARTEMLEA (FDA). Moderate corpus alignment. The trial results will be critical for regulatory submissions, potentially leading to new indications for daridorexant that could enhance its marketability and compliance with treatment guidelines.

Key Risks

Elevated medium regulatory exposure for alcohol use disorder market could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If daridorexant proves effective, it could capture significant market share in a niche segment, impacting revenues for competitors focused on either insomnia or alcohol use disorder independently.
This trial could inform strategic decisions regarding the development of combination therapies and market positioning for sleep medications.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for efficacy in reducing alcohol use and improving sleep metrics compared to placebo.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Drug Trials Snapshots: YARTEMLEA
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Drug Trials Snapshots: PALSONIFY
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Office of New Drugs Custom Medical Queries (OCMQs) for Safety Signal Detection in Clinical Trial Data - 06/23/2026
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

Daridorexant for People With Insomnia and Alcohol Use Disorder Study
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Meaning of Dopaminergic Pathway in Sleep Breathing Disorders.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Global Myofascial Treatment With Focused Shockwave for Non-Specific Low Back Pain: Randomized Control Trial.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Lillyhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Bristol-Myers Squibb initiates Phase 3 trial for KarXT + KarX-EC in Alzheimer's agitation
Humanexa Signalsmedium relevance
Moderate corpus alignment

Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Adaption of a posttraumatic stress disorder intervention for patients who use stimulants and opioids in the opioid treatment programme setting.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Observation of the therapeutic effect of flunarizine capsules combined with the Epley manoeuvre in the treatment of benign paroxysmal positional vertigo.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

alcohol use disorder market
insomnia treatment market

Commercial impact

medium

If daridorexant proves effective, it could capture significant market share in a niche segment, impacting revenues for competitors focused on either insomnia or alcohol use disorder independently.

Regulatory impact

medium

The trial results will be critical for regulatory submissions, potentially leading to new indications for daridorexant that could enhance its marketability and compliance with treatment guidelines.

What to watch

Monitor trial results for efficacy in reducing alcohol use and improving sleep metrics compared to placebo.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.